Detecting Parkinson Disease at Early Stages With Alpha-Synuclein Amplification Assay: Russell Lebovitz, MD, PhD

In 2019, the FDA granted Amprion a Breakthrough Device Designation for use of its SYNTap Biomarker Test in assisting for the diagnosis of Parkinson Disease (PD), becoming commercially available years later in 2021. The test is a first-in-class-qualitative Laboratory Developed Test (LDT) and the only seed amplification assay available to help with the diagnosis of synucleinopathies such as in PD, Lewy Body dementia (LBD), and Alzheimer Disease (AD) with the Lewy Body variant...READ MORE